Jim Cramer Gives His Opinion On NeoGenomics, Yeti And More

On CNBC's "Mad Money Lightning Round," Jim Cramer said that NeoGenomics, Inc. (NASDAQ:NEO) is a good spec, because early diagnostic of cancer is a holy grail.

Cramer is not a buyer of Yeti Holdings Inc (NYSE:YETI) because it's already up 100% for the year.


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Nutanix Inc (NASDAQ:NTNX) is making a little comeback, but Cramer finds it too hard to recommend the stock.

Cadence Design Systems Inc (NASDAQ:CDNS) is overvalued, said Cramer. He added that the company has never been able to put together a systematic year of great numbers. He is not a buyer.

Posted In: MediaCNBCJim CramerMad Moneymad money Lightning Round